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Abstract
BACKGROUND—Sickle cell disease patients are more likely than the general population to
undergo surgery and usually do so at a younger age. Female sickle cell disease patients also have
special gynecological and obstetric issues related to their disease.
METHODS—We collected data through standardized clinical report forms, patient interviews,
and medical records from 509 adult sickle cell disease patients. Logistic regression was used to
estimate the association between multiple variables and each of the surgery types. We also
determined the prevalence and outcomes of pregnancy in 284 women with sickle cell disease in
this population.
RESULTS—Almost 50% of patients aged 18–27 years had had a cholecystectomy. Mean
corpuscular hemoglobin, total bilirubin, and lactate dehydrogenase were significantly higher in the
postcholecystectomy group; 9.5% of 504 individuals had undergone splenectomy. Hematocrit,
body mass index, and red blood cell count were significantly higher in the postsplenectomy group.
Hip replacement had been performed in 9.2% of individuals, with the prevalence increasing as
early as the fourth decade and continuing to increase through the sixth decade of life. A history of
pregnancy was present in 190 women (67%). Of 410 pregnancies, only 53.9% resulted in live
births, 16.6% were voluntarily terminated, and 29.5% were complicated by miscarriage, still birth,
or ectopic implantation.
CONCLUSIONS—Sickle cell disease continues to have a strong effect on the mean age for
common surgeries and impacts pregnancy outcomes. We conclude that this population has a
unique surgical and obstetric history that should be further studied to provide insight into
potentially more effective preventive approaches to end-organ damage.
Keywords
Cholecystectomy; Pregnancy; Pregnancy complications; Sickle cell disease; Surgery
© 2008 Elsevier Inc. All rights reserved.
Requests for reprints should be addressed to Soheir Adam, MD, Duke Comprehensive Sickle Cell Center, Duke University, Box 3939,
Durham, NC 27710. soheir.adam@duke.edu.
NIH Public Access
Author Manuscript
Am J Med. Author manuscript; available in PMC 2014 February 19.
Published in final edited form as:














Sickle cell disease is an inherited hemoglobinopathy, resulting from a single nucleotide
change in the gene encoding the β chain of hemoglobin. The mutant β globin chains (HbS)
render the red cells more prone to hemolysis, due at least in part to polymerization of
deoxyhemoglobin. In addition, HbS red cells contribute to the process of vasoocclusion in
both large and small vessels. Adhesion of HbS cells results in endothelial damage and
upregulation of adhesion molecules, which stimulates further red cell and leukocyte
adhesion, as well as the release of various cytokines and proteolytic enzymes. This process
ultimately leads to severe anemia and impaired tissue perfusion, resulting in a broad array of
end-organ complications. Chronic hemolysis also results in pigment gallstone formation and
cholelithiasis. Splenic sequestration and splenic pooling can be a major cause of morbidity
and mortality in children with sickle cell disease and in adults with other sickle cell
syndromes and often warrant splenectomy. Hypersplenism, splenic infarction, and increased
transfusion requirements also might be indications for splenectomy.1 By age 35 years, about
50% of sickle cell disease patients have developed femoral head necrosis. Osteonecrosis of
the femoral head results from infarction of the cancellous trabeculae. The femoral head is
more commonly affected than other sites due to its weight-bearing function.2
Sickle cell disease patients are much more likely than the general population to undergo
surgical procedures in their lifetime,3 and the age at which surgery is performed is younger
than that of the general population.4,5 The Cooperative Study of Sickle Cell Disease
reported the course and outcome of all surgical procedures performed for 717 sickle cell
disease patients during the period from 1978 to 1988.6 For more than 2 decades, there have
been no further reports on the prevalence of major surgeries in this population.
The aim of the present study was to determine the current prevalence of surgical procedures
in an adult sickle cell disease population, in view of both improved medical care and the
advent of hydroxyurea therapy for sickle cell disease. In addition, we examined patient
characteristics associated with history of previous surgeries. We also analyzed the
prevalence and outcomes of pregnancy in sickle cell disease.
METHODS
Over a period of 5 years (2002–2007), 509 unrelated adult patients were enrolled in the
study after informed consent was obtained. There were 21 patients with Sβ0 thalassemia and
488 patients who were homozygous for HbS. The patient population came primarily from 3
major centers in the southeast United States: Duke University, Durham, NC; University of
North Carolina, Chapel Hill, NC; and Emory University, Atlanta, GA. A small number of
patients also were enrolled at East Carolina University, Greenville, NC, and the Carolinas
Medical Center, Charlotte, NC. The patients enrolled at Duke University Medical Center,
University of North Carolina, and Emory University represent more than half the HbSS
patients followed regularly at these centers.
Data Collection
Medical history was obtained by both patient interviews and review of medical records,
using standardized case report forms, and information was then entered into our Pedigene
database. Other data collected included demographics, baseline hematology and chemistry
laboratory values, vital signs, results of physical examination, body mass index (BMI), and
current medications.
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Contingency tables were used to provide descriptive frequencies of the surgical and obstetric
outcomes. Logistic regression was used to identify statistically significant associations
between surgical outcomes and possible predictor and related outcome variables. All
analyses were conducted using SAS version 9.1 (PROC FREQ and PROC LOGISTIC; SAS
Institute Inc., Cary, NC).
RESULTS
Among all surgeries studied, cholecystectomy was 5 times more common than other
surgeries, while total hip replacement tended to be performed latest in life (Figure 1).
Cholecystectomy
Cholecystectomy was the most commonly reported surgery in this population (291/509,
57.17%). Among patients 18–47 years of age, 47.5% of subjects had already had a
cholecystectomy; and 69% of those who were 47 years and older had undergone the
procedure (Figure 1). The likelihood of having had a cholecystectomy increased with each
year of age over 18 (odds ratio [OR] 1.028 per year). The mean corpuscular volume, total
bilirubin, and lactate dehydrogenase were significantly higher for those who had had
cholecystectomy than those without cholecystectomy (P = .008, P = .008, and P = .006
respectively, Table 1), although the reticulocyte count was not different between the 2
groups. The odds of having had a cholecystectomy increased for each femtoliter (fl) increase
in mean corpuscular hemoglobin (OR 1.026). Also, the likelihood of having had a
cholecystectomy increased with increases in serum bilirubin (OR 1.128 per mg/dL increase).
Furthermore, the odds of having had a cholecystectomy increased by 1.028 for each 50-unit
increase in lactate dehydrogenase. Interestingly, there was no relationship between BMI or
sex and cholecystectomy, despite the association of these variables with cholecystectomy in
the general population.
Splenectomy
A history of surgical splenectomy was reported by 48 of 504 study subjects (9.52%) for
whom a response was recorded; 43 of 48 post-splenectomy subjects were ages 18–47
(Figure 2). The percentage of Sβ0 patients who had had splenectomy was 43% (9/21), while
only 8.1% (39/483) of SS patients reported having had a splenectomy. The hematocrit was
found to be significantly higher in the post-splenectomy group (26.3 vs 24.3) (P = .017).
Interestingly, individuals with a higher BMI also were more likely to have had surgical
splenectomy (P = .028, Table 2).
Total Hip Replacement
Hip replacement had been performed in 47/509 (9.23%) individuals, and 85% of these
reported having it by the age of 57 years (Figure 1). There was no significant difference
between the BMI values in those with a history of total hip replacement and those with no
history of total hip replacement (25.09 ± 4.3 and 23.8 ± 4.9, respectively, Table 3). In
addition, there were no differences in hematology or hemolysis-associated laboratory values
between patients who had or had not undergone total hip replacement.
Obstetrical History and Outcomes
Of the 284 women included in this analysis, 190 subjects (66.9%) reported a history of a
total of 410 pregnancies, resulting in an average pregnancy rate of 2.16 for those who
became pregnant at least once, but only 1.44 for all female subjects. The mean age at first
delivery was 23.7 years. Of all reported pregnancies, 221 resulted in live births (53.9%) and
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121 (29.51%) ended in miscarriages, stillbirths, or ectopic implantation. There were 68
(16.59%) voluntary terminations (Table 4).
DISCUSSION
Pigment gallstones originating from chronic hemolysis affect 20% of children and more than
80% of adults with sickle cell disease.7 Gallstones cause cholecystitis and recurrent attacks
of abdominal pain. These frequent complications have historically made cholecystectomy
the most common surgical procedure in sickle cell disease. In this study, we also found
cholecystectomy to be the most commonly performed surgery. Almost one fifth of patients
aged 18–27 years had undergone cholecystectomy. Recently, another group of investigators
examined the 2004 Nationwide Inpatient Sample from the Healthcare Cost and Utilization
Project and found that the mean age for cholecystectomy was 52.8 ± 0.2 years in the general
population (Reed S, Chou SH, personal communication). Clearly, patients with sickle cell
disease continue to undergo cholecystectomy at a far younger age than do other populations
in the United States. Interestingly, the levels of bilirubin and lactate dehydrogenase were
significantly higher in patients who had had cholecystectomy, suggesting that differences in
hemolytic rate and possibly bilirubin metabolism affect the lifetime need for
cholecystectomy, rather than just the age at cholecystectomy, as has been reported
recently.8–10
Only a small number of our study population (48/504, 9.5%) had had their spleens surgically
removed. Interestingly, splenectomy had occurred at a much higher rate in Hb Sβ0 than in
Hb SS patients (43% in Sβ0 and 8% in SS). Therefore, the odds of having had a splenectomy
were 9.17 times higher for individuals with Hb Sβ0 compared with those with Hb SS (P = .
0001). Nationwide in 2004, the mean age of splenectomy was 17 years for sickle cell disease
patients (Chou, Reed and colleagues, personal communication), as compared with 45 years
in the healthy population. However, the nationwide data are likely to include patients with
Hb SC and Hb Sβ+ thalassemia as well, and such patients are more likely to undergo
splenectomy at a later age than those with Hb SS. Nevertheless, we were surprised to find
that the cumulative prevalence of splenectomy increased beyond age 27 years, even in a
population limited to individuals with Hb SS and Hb Sβ0 thalassemia. This may reflect the
possibility that use of splenectomy in sickle cell disease has decreased over time. The
hematocrit also was significantly higher in those who had had splenectomy, despite the fact
that in adulthood the vast majority of patients lack functional spleens; this appears to reflect
the relative increase of splenectomy among the Hb Sβ0 patients. Although Hb SS patients
who were surgically splenectomized had a higher hematocrit than similar patients without
splenectomy (25.43 vs 24.22), a greater difference was observed for Hb Sβ0 patients (29.46
vs 26.58). Interestingly, splenectomized patients had a significantly higher BMI than
nonsplenectomized subjects. This may be explained by the negative effect of hypersplenism
and the hypercatabolic symptoms of an enlarged spleen on weight gain during childhood. In
addition, Hb Sβ0 patients were found to have higher body mass indices, thus skewing the
BMI results between the 2 groups (Hb Sβ0 mean BMI = 26.50, Hb SS mean = 23.91, P = .
0403 controlling for age). Alternatively, individuals with higher hemoglobin levels may
have increased risk of splenectomy and higher BMIs. Bone disease is one of the major
complications of sickle cell disease. This includes bone infection, bone infarction, and
osteonecrosis of the femoral and, less commonly, humeral heads.4
About half of the sickle cell disease population is expected to develop osteonecrosis by the
age of 35 years.2 The persistence of disabling pain that is unresponsive to conservative
measures is usually considered an indication for arthroplasty.11 Hip arthroplasty is
performed at a younger age in this population.12,13 While the mean age for hip replacement
nationwide for all individuals is 69.8 years (Reed S, Chou SH, personal communication), the
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prevalence of hip arthroplasty in sickle cell disease appears to increase significantly as early
as the fourth and fifth decades of life (Figures 1, 2). Furthermore, although it is well
documented in the literature that obesity is a major risk factor for osteonecrosis in young
adults,14–17 there was no correlation between BMI and hip replacement surgery in our study.
However, this may be due to the small number of patients who had had hip surgery (n = 47),
as well as to the wide variability in BMI values in our patient population.18
Overall, this study showed unique correlations between different types of surgery, patient
age, and specific laboratory values. As shown in Figure 2, cholecystectomy was the most
commonly reported surgery in all group ages. Interestingly, the prevalence of all 3 types of
surgeries appeared to plateau as patients aged, as shown in Figure 1. Around 40% of patients
below the age of 28 years had a history of cholecystectomy, and most cholecystectomies
appear to have been performed by age 50 years in this population. On the other hand,
splenectomies were largely performed before age 40 years. Total hip replacements were
rarely performed in patients younger than 37 years and also were rarely performed in
patients above the age of 57 years.
The average rate of pregnancy was found to be 1.44 among all sickle cell disease women
included in the analysis and 2.15 among those who had been pregnant. In the Cooperative
Study of Sickle Cell Disease, 320 pregnancies were reported among 155 women, for a
similar pregnancy rate of 2.1.19 The mean age at delivery was comparable to that in the
general population, for which the mean age at delivery of all pregnancies is 27.7 ± 0.1 years.
Female sickle cell disease patients are known to have an increased incidence of pregnancy-
related complications. The rate of preterm delivery before 36 weeks of gestation has been
estimated to be 30%–50% in sickle cell disease, with the average gestational age at delivery
being 34 weeks.20 Earlier studies also have shown that more than one third of pregnancies in
women with sickle cell disease end in abortion, stillbirth, or neonatal death.19 In the report
from the Cooperative Study of Sickle Cell Disease, 28.5% of pregnancies were terminated
electively and 6.5% spontaneously. Among 200 live births reported, 20% of the newborns
were of low birth weight. The reported rate of live births in the general African-American
population was 67.4/1000 in 2002.21 In our study, women opted for voluntary terminations
in only 16.6% of pregnancies, a number lower than that observed in the Cooperative Study
of Sickle Cell Disease. This observation might reflect the more optimistic attitude of both
health care providers and patients about pregnancy in this population. However,
miscarriages, stillbirths, and ectopic implantations occurred in 29.5%, while only 53.9% of
pregnancies resulted in live births. Available data indicate that around 65% of pregnancies
in the United States result in live births. Thus, while the percentage of live births in our
study is actually slightly lower than that reported in the Cooperative Study of Sickle Cell
Disease, also it remains considerably lower than in the general American population.
We conclude, therefore, that as sickle cell disease patients live longer, the need for better
medical and surgical care for this population increases. The surgical and obstetric data in
adults with sickle cell disease in our study demonstrate little positive change since the
Cooperative Study of Sickle Cell Disease report of data collected approximately 2 decades
previously, despite the advent of hydroxyurea therapy. Future research should focus on
developing preventive measures for sickle cell disease complications in order to slow organ
damage and reduce the need for surgery, especially arthroplasty. New agents also need to be
developed to reduce the rate of hemolysis and, as a consequence, the incidence of
cholelithiasis, thus deferring cholecystectomy. Other preventive measures to minimize vaso-
occlusion and bone necrosis should be investigated in order to obviate the need for
splenectomy and total hip replacement at relatively young ages in sickle cell disease
patients. Ideally, genetic polymorphisms associated with certain clinical complications in
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sickle cell disease patients need to be identified, in order eventually to allow the adoption of
individually tailored prophylaxis in this population. We hope that risk stratification and
preemptive intervention will reduce the need for surgery and the risk of negative outcomes
of pregnancy in sickle cell disease in the future.
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• Sickle cell disease patients undergo cholecystectomy and hip replacement at
ages much younger than the general population.
• The prevalence of all types of surgeries appears to plateau as patients age.
• The cumulative prevalence of splenectomy increased beyond the age of 27 years
in Hb SS and Sβ0 disease.
• The live birth rate for mothers with sickle cell disease remains considerably
lower than for the general African-American population.
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Cumulative prevalence of surgical histories by age. The prevalence of cholecystectomy,
splenectomy, and total hip replacement is shown. The frequency of all 3 types of surgeries
appeared to plateau as patients aged.
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Number of surgeries performed in each age group. The numbers of individuals who had had
surgery in different age groups is compared. While a history of cholecystectomy is far more
common than history of other surgeries in all groups, above age 38 years, a history of total
hip replacement is more common than a history of splenectomy.
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Table 1
Correlation of Clinical and Laboratory Variables with Prevalence of Cholecystectomy
Variable Cholecystectomy No Cholecystectomy P Value* OR (CI)†
Sex (% female) 59.1 49.5 .081
Hb (g/dL) 8.28 ± 1.45 8.44 ± 1.52 .466
Hct 24.25 ± 4.50 24.67 ± 4.53 .573
MCV (fl) 91.59 ± 12.13 88.04 ± 10.40 .008 1.026 (1.007–1.046)
Abs. retic. count (× 103/µL) 298.34 ± 131.70 302.30 ± 134.16 .983
T. bilirubin (mg/dL) 3.54 ± 3.17 2.93 ± 2.04 .005 1.128 (1.037–1.226)
LDH (U/L)‡ 896.84 ± 572.07 742.82 ± 489.97 .006 1.028 (1.008–1.048)
BMI 23.93 ± 4.85 23.89 4.93 .642
OR = odds ratio; CI = confidence interval; Hb = hemoglobin; Hct = hematocrit; MCV = mean corpuscular hemoglobin; Abs. retic. count = absolute
reticulocyte count; T. bilirubin = total bilirubin; LDH = lactate dehydrogenase; BMI = body mass index.
*
All P values were obtained after controlling for age.
†
OR: per unit of measure.
‡
Odds ratio per 50 U/L LDH change.
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Table 2
Correlation of Clinical and Laboratory Variables with Prevalence of Splenectomy
Variable Splenectomy No Splenectomy P Value* OR (CI)†
Sex (% female) 58.3% 55.0% .205
RBC (× 109/L) 3.07 ± 0.9 2.72 ± 0.6 .004 2.025 (1.259–3.257)
Hb (g/dL)‡ 8.69 ± 1.9 8.32 ± 1.4 .180
Hct‡ 26.31 ± 5.6 24.27 ± 4.4 .017 1.096 (1.017–1.182)
MCV(fl) 87.12 ± 12.0 90.37 ± 11.5 .122
Abs. retic. count (× 103/µL) 280.14 ± 101.8 301.43 ± 135.2 .368
T. bilirubin (mg/dL) 2.60 ± 1.9 3.31 ± 2.8 .085
LDH (U/L) 912.30 ± 510.8 824.12 ± 547.9 .334
BMI 25.50 ± 5.6 23.75 ± 4.8 .028 1.077 (1.008–1.151)
CI = confidence interval; RBC = red blood cell count; Hb = hemoglobin; Hct = hematocrit; MCV = mean corpuscular hemoglobin; Abs. Retic.
Count = absolute reticulocyte count; T. bilirubin = total bilirubin; LDH = lactate dehydrogenase; BMI = body mass index; OR = odds ratio.
*
All P values were obtained after controlling for age.
†
OR: per unit of measure.
‡
Hb SS only.
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Table 3
Correlation of Clinical and Laboratory Variables with Prevalence of Total Hip Replacement (THR) Surgery
Variable THR No THR P Value*
Sex (% female) 57.4% 55.2% .452
Hb (g/dL) 8.49 ± 1.5 8.33 ± 1.5 .109
Hct 24.91 ± 4.6 24.39 ± 4.5 .146
MCV (fl) 91.25 ± 9.5 89.99 ± 11.7 .933
Abs. Retic. Count (× 103/µL) 306.39 ± 193.8 298.21 ± 125.4 .323
T. bilirubin (mg/dL) 2.44 ± 1.6 3.55 ± 2.8 .158
LDH (U/L) 789.62 ± 454.2 834.60 ± 550.7 .464
BMI 25.09 ± 4.3 23.82 ± 4.9 .562
Hb = hemoglobin; Hct = hematocrit; MCV = mean corpuscular hemoglobin; Abs. Retic. Count = absolute reticulocyte count; T. bilirubin = total
bilirubin; LDH = lactate dehydrogenase; BMI = body mass index; OR = odds ratio; CI = confidence interval.
*
All P values were obtained after controlling for age.
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